Author

B. N. Lambrecht

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2 Organism:human· 1

Frequent Co-Authors

A. Choi· 1 shared A. Garcia-Sastre· 1 shared A. Uvyn· 1 shared A.-S. Desmet· 1 shared B. G. De Geest· 1 shared B. Schepens· 1 shared C. De Wolf· 1 shared C. Lonigro· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Choi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike

S. De Cae, I. Van Molle, L. van Schie, S. R. Shoemaker, J. Deckers, N. Debeuf, S. Lameire, W. Nerinckx, K. Roose, D. Fijalkowska, S. Devos, A.-S. Desmet, J. C. Zavala Marchan, T. Venneman, G. H. Ghassabeh, , B. Schepens

The paper identifies ultrapotent SARS-CoV-2-neutralizing nanobodies that bind a conserved epitope on the spike protein, showing therapeutic efficacy in hamsters.

bioRxiv · Mar 10, 2023 · PreprintMicrobiology

Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine

S. Jangra, J. De Vrieze, A. Choi, R. Rathnasinghe, G. Laghlali, A. Uvyn, S. Van Herck, L. Nuhn, K. Deswarte, Z. Zhong, N. Sanders, S. Lienenklaus, S. David, S. Strohmeier, F. Amanat, , M. Schotsaert

This paper demonstrates that a novel TLR7/8 agonist adjuvant enables single-shot protection against SARS-CoV-2 and influenza in mice using recombinant spike protein and inactivated vaccines.

bioRxiv · Oct 23, 2020Microbiology